Insmed Inc’s filing revealed that its Chief Operating Officer Adsett Roger unloaded Company’s shares for reported $0.15 million on Jan 12 ’24. In the deal valued at $28.63 per share,5,251 shares were sold. As a result of this transaction, Adsett Roger now holds 148,559 shares worth roughly $3.61 million.
Then, Flammer Martina M.D. sold 4,667 shares, generating $133,616 in total proceeds. Upon selling the shares at $28.63, the Chief Medical Officer now owns 106,898 shares.
Before that, Adsett Roger sold 3,536 shares. Insmed Inc shares valued at $102,190 were divested by the Chief Operating Officer at a price of $28.90 per share. As a result of the transaction, Adsett Roger now holds 153,810 shares, worth roughly $3.74 million.
Wolfe Research initiated its Insmed Inc [INSM] rating to an Outperform in a research note published on February 15, 2024; the price target was $42. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Guggenheim started covering the stock on July 26, 2023. It rated INSM as “a Buy”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock fall -1.94% to $24.32. Over the last five days, the stock has lost -10.75%. Insmed Inc shares have fallen nearly -21.52% since the year began. Nevertheless, the stocks have risen 35.87% over the past one year. While a 52-week high of $32.00 was reached on 01/02/24, a 52-week low of $17.41 was recorded on 04/19/24. SMA at 50 days reached $27.38, while 200 days put it at $25.72. A total of 5.53 million shares were traded, compared to the trading of 2.3 million shares in the previous session.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 23.27, which if violated will result in even more drops to 22.23. On the upside, there is a resistance level at 25.62. A further resistance level may holdings at 26.92. The Relative Strength Index (RSI) on the 14-day chart is 31.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.86, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.61%. Stochastics %K at 9.47% indicates the stock is a buying.
The most recent change occurred on December 09, 2022 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
